Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia

Blood

Volumn 99, Issue 6, 2002, Pages 2255-2258

  Devine, Steven M ^a,b   Hoffman, Ron ^a   Verma, Amit ^a   Shah, Rajul ^a   Bradlow, Basil A ^a   Stock, Wendy ^a   Maynard, Vera ^a   Jessop, Ellen ^a   Peace, David ^a   Huml, Marianne ^a   Thomason, Deana ^a   Chen, Yi Hsiang ^a   Van Besien, Koen ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b M/C 787   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; MELPHALAN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE REPORT; CHIMERA; EVALUATION; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; NEUTROPHIL; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTE;

EID: 0037085757     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.6.2255     Document Type: Article

References (25)

1. Myelofibrosis with myeloid metaplasia
2. Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines
3. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County Study, 1976-1995
4. Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system
5. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis
6. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival
7. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia
8. Long term treatment of myeloproliferative disease with interferon-alpha-2b: Feasibility and efficacy
9. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study
10. Myelofibrosis with myeloid metaplasia
11. Stem-cell transplantation for myelofibrosis
12. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
13. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
14. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
15. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
16. Relevance of marrow fibrosis in bone marrow transplantation: A retrospective analysis of engraftment
17. Myeloproliferative disorders: Myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia
18. Regimen-related toxicity in patients undergoing bone marrow transplantation
19. 1994 Consensus Conference on Acute GVHD Grading
20. Chronic graft-versus-host disease and other late complications of bone marrow transplantation
21. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection
22. Quantitation of bone marrow reticulin: A normal range
23. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis
24. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: Demonstration of a graft-versus-myelofibrosis effect
25. Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: Evidence for a 'graft vs. myelofibrosis' effect